Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Hematology | Musculoskeletal | Family Medicine
 Disease Category: Multiple Myeloma
Location: United States, CA

Trial Information

An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of MLN9708 Administered Twice-weekly in Combination with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment

The purpose of this study is to identify any side effects with the study drug combination (MLN9708, Lenalidomide, and low-dose Dexamethasone) when MLN9708 is given at different doses. The study is also trying to find out the effects, good and/or bad the study drug combination has on your type of cancer. The length of time you will be in the study will depend upon how you are feeling, how well you tolerate the study drug combination and how your disease responds to the study drug combination. You can continue receiving the study drug combination for up to 16 cycles (a cycle lasts 21 days) depending on how your body responds. If you are responding to therapy you could continue to receive MLN9708 alone as long as your disease continues to respond to it. After your treatment on this study is over you will continue to be followed indefinitely.

Patient Inclusion/Exclusion Criteria:


- See http://clinicaltrials.coh.org for additional information.


City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)

View Map

Research Center Information: City of Hope

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.